Literature DB >> 15289152

Conjunctival hyperemia associated with bimatoprost use: a histopathologic study.

Bruno C Leal1, Felipe A Medeiros, Fabrício W Medeiros, Ruth M Santo, Remo Susanna.   

Abstract

PURPOSE: To evaluate histopathologic signs of conjunctival inflammation in patients with conjunctival hyperemia induced by bimatoprost treatment.
DESIGN: Prospective interventional study.
METHODS: The study included 15 eyes of 15 patients scheduled for cataract surgery. Patients in the treatment group (n = 9) exhibited trace to moderate conjunctival hyperemia when treated with bimatoprost 0.03% every day for 15 to 30 days before surgery. The control group (n = 6) included untreated patients with no ocular disease other than cataract. Conjunctival biopsies were obtained for histologic evaluation with light microscopy.
RESULTS: Vascular congestion was observed in biopsies from 7 patients (78%) in the bimatoprost group and 5 patients (83%) in the control group. Signs of inflammation were found in biopsies from 2 patients (22%) in the bimatoprost group and 2 patients (33%) in the control group.
CONCLUSIONS: Histopathologic signs of inflammation were no more frequent in conjunctival specimens from bimatoprost-treated patients with trace to moderate hyperemia than in those from untreated control subjects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289152     DOI: 10.1016/j.ajo.2004.03.006

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%.

Authors:  Abayomi B Ogundele; David Earnest; Marsha A McLaughlin
Journal:  Clin Ophthalmol       Date:  2010-07-30

2.  A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost.

Authors:  E Randy Craven; Ching-Chi Liu; Amy Batoosingh; Rhett M Schiffman; Scott M Whitcup
Journal:  Clin Ophthalmol       Date:  2010-12-06

3.  An effect of bimatoprost: adverse for some, therapeutic for others.

Authors:  Ashok Kumar Dubey
Journal:  Int J Trichology       Date:  2011-07

4.  Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%).

Authors:  Moataz E Gheith; Jason R Mayer; Ghada A Siam; Daniela S Monteiro de Barros; Tricia L Thomas; L Jay Katz
Journal:  Clin Ophthalmol       Date:  2008-03

Review 5.  The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies.

Authors:  Nathan M Radcliffe
Journal:  Clin Ophthalmol       Date:  2014-12-12

Review 6.  Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.

Authors:  Daniel Lee; Anand V Mantravadi; Jonathan S Myers
Journal:  Clin Ophthalmol       Date:  2017-07-10

Review 7.  Preservatives in glaucoma medication.

Authors:  David W Steven; Pouya Alaghband; Kin Sheng Lim
Journal:  Br J Ophthalmol       Date:  2018-07-04       Impact factor: 4.638

8.  Conjunctival changes and inflammatory aspects in rabbits' conjunctivas induced by fixed combinations of prostaglandin analogues and timolol maleate.

Authors:  Nubia Vanessa Lima de Faria; Heloisa Helena Russ; Palloma Rose; Lucia Noronha; Paulo Augusto Mello; Fabiano Montiani-Ferreira; Sebastião Cronemberger Sobrinho
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-01-28

9.  An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial.

Authors:  Donald R Nixon; Susan Simonyi; Meetu Bhogal; Christopher S Sigouin; Andrew C Crichton; Marino Discepola; Cindy Ml Hutnik; David B Yan
Journal:  Clin Ophthalmol       Date:  2012-12-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.